EDP Sciences logo
Submit your paper
Search
Menu
All issues Volume 54 / No 3 (September 2022) J Extra Corpor Technol, 54 3 (2022) 223-234 References
Free Access
Issue
J Extra Corpor Technol
Volume 54, Number 3, September 2022
Page(s) 223 - 234
DOI https://doi.org/10.1051/ject/202254223
Published online 15 September 2022
  1. Morens DM, Fauci AS. Emerging pandemic diseases: How we got to COVID-19. Cell. 2020;182:1077–92. [CrossRef] [Google Scholar]
  2. Giri S, Sen S, Singh R, et al. Current challenges in different approaches to control COVID-19: A comprehensive review. Bull Natl Res Cent. 2022;46:47. [CrossRef] [Google Scholar]
  3. Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost. 2020;18:1559–61. [CrossRef] [Google Scholar]
  4. Foley JH, Conway EM. Cross talk pathways between coagulation and inflammation. Circ Res. 2016;118:1392–408. [CrossRef] [PubMed] [Google Scholar]
  5. Milenkovic M, Hadzibegovic A, Kovac M, et al. D-dimer, CRP, PCT, and IL-6 levels at admission to ICU can predict in-hospital mortality in patients with COVID-19 pneumonia. Oxid Med Cell Longev. 2022;2022:8997709. [CrossRef] [Google Scholar]
  6. Moores LK, Tritschler T, Brosnahan S, et al. Thromboprophylaxis in patients with COVID-19. A brief update to the CHEST guideline and expert panel report. Chest. 2022;162:213–25. [CrossRef] [Google Scholar]
  7. Lequier L, Annich G, Al-Ibrahim O, et al. The ELSO Anticoagulation Guideline. Available at: https://www.elso.org/portals/0/files/elsoanticoagulationguideline8-2014-table-contents.pdf. Accessed March 15, 2022. [Google Scholar]
  8. Hall CA, Jacobs JP, Stammers AH, et al. Multi-institutional analysis of 505 COVID-19 patients treated with ECMO: Predictors of survival. Ann Thorac Surg. 2022;114:61–8. [CrossRef] [Google Scholar]
  9. Jacobs JP, Stammers AH, St. Louis J, et al. Multi-institutional analysis of 200 consecutive patients with COVID-19 and severe pulmonary compromise treated with extracorporeal membrane oxygenation: Outcomes and trends over time. Ann Thorac Surg. 2021;67:496–502. [Google Scholar]
  10. Esper SA, Welsby IJ, Subramaniam K, et al. Adult extracorporeal membrane oxygenation: An international survey of transfusion and anticoagulation techniques. Vox Sang. 2017;112:443–52. [CrossRef] [Google Scholar]
  11. Ranucci M, Ballotta A, Kandil H, et al. Surgical and Clinical Outcome Research Group. Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation. Crit Care. 2011;15:R275. [CrossRef] [PubMed] [Google Scholar]
  12. Rivosecchi RM, Arakelians AR, Ryan J, et al. Comparison of anticoagulation strategies in patients requiring venovenous extracorporeal membrane oxygenation: Heparin versus bivalirudin. Crit Care Med. 2021;49:1129–36. [Google Scholar]
  13. Lee CJ, Ansell JE. Direct thrombin inhibitors. Br J Clin Pharmacol. 2011;72:581–92. [CrossRef] [Google Scholar]
  14. Lázaro-García A, Martínez-Alfonzo I, Vidal-Laso R, et al. A journey through anticoagulant therapies in the treatment of left ventricular thrombus in post-COVID-19 heparin-induced thrombocytopenia: A case report. Hematology. 2022;27:318–21. [CrossRef] [Google Scholar]
  15. Guo Z, Sun L, Li B, et al. Anticoagulation management in severe coronavirus disease 2019 patients on extracorporeal membrane oxygenation. J Cardiothorac Vasc Anesth. 2021;35:389–97. [CrossRef] [Google Scholar]
  16. Seeliger B, Doebler M, Hofmaenner DA, et al. Intracranial hemorrhages on extracorporeal membrane oxygenation: Differences between COVID-19 and other viral acute respiratory distress syndrome. Crit Care Med. 2022;50:e526–38. [CrossRef] [PubMed] [Google Scholar]
  17. Doyle AJ, Hunt BJ, Sanderson B, et al. A comparison of thrombosis and hemorrhage rates in patients with severe respiratory failure due to coronavirus disease 2019 and influenza requiring extracorporeal membrane oxygenation. Crit Care Med. 2021;49:e663–72. [Google Scholar]
  18. McMichael ABV, Ryerson LM, Ratano D, et al. 2021 ELSO Adult and Pediatric Anticoagulation Guidelines. ASAIO J. 2022;68:303–10. [CrossRef] [PubMed] [Google Scholar]
  19. Badulak J, Antonini MV, Stead CM, et al. ELSO COVID-19 working group members. Extracorporeal membrane oxygenation for COVID-19: Updated 2021 guidelines from the Extracorporeal Life Support Organization. ASAIO J. 2021;67:485–95. [CrossRef] [PubMed] [Google Scholar]
  20. Sattler LA, Boster JM, Ivins-O’Keefe KM, et al. Argatroban for anticoagulation in patients requiring venovenous extracorporeal membrane oxygenation in Coronavirus Disease 2019. Crit Care Explor. 2021;3:e0530. [CrossRef] [Google Scholar]
  21. Seelhammer TG, Rowse P, Yalamuri S. Bivalirudin for maintenance anticoagulation during venovenous extracorporeal membrane oxygenation for COVID-19. J Cardiothorac Vasc Anesth. 2021;35:1149–53. [CrossRef] [Google Scholar]
  22. Trigonis R, Smith N, Porter S, et al. Efficacy of bivalirudin for therapeutic anticoagulation in COVID-19 patients requiring ECMO support. J Cardiothorac Vasc Anesth. 2022;36:414–8. [CrossRef] [Google Scholar]
  23. R Core Team. (2021). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available at: https://www.R-project.org/. [Google Scholar]
  24. Subirana I, Sanz H, Vila J. Building bivariate tables: The ‘compareGroups’ package for R. J Stat Softw. 2014;57:1–16. [CrossRef] [Google Scholar]
  25. Harrell FE Jr. (2021). ‘rmsb’: Bayesian Regression Modeling Strategies. R package version 0.0.2. Available at: https://CRAN.R-project.org/package=rmsb. [Google Scholar]
  26. Usman AA, Han J, Acker A, et al. A case series of devastating intracranial hemorrhage during venovenous extracorporeal membrane oxygenation for COVID-19. J Cardiothorac Vasc Anesth. 2020;34:3006–12. [CrossRef] [Google Scholar]
  27. Goligher EC, Bradbury CA, McVerry BJ, et al. Therapeutic anticoagulation with heparin in critically ill patients with COVID-19. N Engl J Med. 2021;385:777–89. [CrossRef] [PubMed] [Google Scholar]
  28. Ten Cate H. Surviving COVID-19 with heparin? N Engl J Med. 2021;385:845–46. [CrossRef] [PubMed] [Google Scholar]
  29. Nunez JI, Gosling AF, O’Gara B, et al. Bleeding and thrombotic events in adults supported with venovenous extracorporeal membrane oxygenation: An ELSO registry analysis. Intensive Care Med. 2022;48:213–24. [CrossRef] [PubMed] [Google Scholar]
  30. Stokes JW, Gannon WD, Sherrill WH, et al. Bleeding, thromboembolism, and clinical outcomes in venovenous extracorporeal membrane oxygenation. Crit Care Explor. 2020;2:e0267. [CrossRef] [Google Scholar]
  31. Cai Z, Greene MI, Zhu Z, et al. Structural features and PF4 functions that occur in heparin-induced thrombocytopenia (hit) complicated by COVID-19. Antibodies (Basel). 2020;9:52. [CrossRef] [Google Scholar]
  32. Kalbhenn J, Glonnegger H, Wilke M, Bansbach J, Zieger B. Hypercoagulopathy, acquired coagulation disorders and anticoagulation before, during and after extracorporeal membrane oxygenation in COVID-19: A case series. Perfusion. 2021;36:592–602. [CrossRef] [PubMed] [Google Scholar]
  33. Burstein B, Wieruszewski PM, Zhao YJ, Smischney N. Anticoagulation with direct thrombin inhibitors during extracorporeal membrane oxygenation. World J Crit Care Med. 2019;8:87–98. [CrossRef] [Google Scholar]
  34. Ranucci M. Bivalirudin and post-cardiotomy ECMO: A word of caution. Crit Care. 2012;16:427. [CrossRef] [PubMed] [Google Scholar]
  35. Robson R, White H, Aylward P, Frampton C. Bivalirudin pharmacokinetics and pharmacodynamics: Effect of renal function, dose, and gender. Clin Pharmacol Ther. 2002;71:433–39. [CrossRef] [PubMed] [Google Scholar]
  36. Aliter KF, Al-Horani RA. Thrombin inhibition by argatroban: Potential therapeutic benefits in COVID-19. Cardiovasc Drugs Ther. 2021;35:195–203. [CrossRef] [PubMed] [Google Scholar]
  37. Pieri M, Quaggiotti L, Fominskiy E, et al. Anticoagulation strategies in critically-ill SARS-CoV-2 patients: The role of direct thrombin inhibitors. J Cardiothorac Vasc Anesth. 2022;36:2961–67. [CrossRef] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.